News

Covidien TurboHawk Clinical Study Directional Atherectomy Effective PAD Therapy

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online in the ...

Directional atherectomy is safe and effective as a frontline therapy for the treatment of peripheral arterial disease (PAD), according to a landmark Covidien study published online today in the...

Teleflex Inc.’s subsidiary Hotspur Technologies Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Arrow GPSCath Balloon Dilatation Catheters designed for use...

Biotronik Enrollment Completion SFA Arm BIOFLEX-I Study Pulsar-18 4-French

Biotronik announced the completion of patient enrollment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an U.S. Food and Drug Administration (FDA)-approved...

Biotronik BIOLUX 4Ever Clinical Trial Pulsar-18 SES Passeo-18 Lux DRB PAD Cath

Biotronik announced that the first patient has been enrolled in the investigator-initiated BIOLUX 4EVER trial. 

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. 

A new series of expert consensus recommendations developed by the Society for Cardiovascular Angiography and Interventions (SCAI) will help physicians determine the best course of action for...

July 18, 2014 — Avinger announced that John Pigott, M.D., of Jobst Vascular Institute, Toledo, Ohio, enrolled the first patient in the VISION trial, a global investigational device exemption (IDE...

July 11, 2014 — Cordis Corp. announced the launch of its Saber PTA (percutaneous transluminal angioplasty) dilatation catheter for the treatment of patients with peripheral arterial disease (PAD...

FDA Recommendation Lutonix Drug Coated Balloon Catheter

C. R. Bard Inc. announced that the U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix...

New appropriate use expert consensus documents developed by the Society for Cardiovascular Angiography and Interventions (SCAI) provide guidance on treating the most common form of peripheral...

Medtronic announced it is purchasing Covidien in a cash-and-stock deal for $42.9 billion. Once the transaction is completed, Medtronic will have significantly advanced its position as a premier...

June 5, 2014 — Mercator MedSystems is in the midst of its prospective, 300-patient, 30-site DANCE (Dexamethasone to the Adventitia to eNhance Clinical Efficacy) clinical trial to study a new...

May 16, 2014 — In a move to expand significantly its portfolio of solutions for peripheral interventions, Boston Scientific Corp. has entered into a definitive agreement to acquire the...

May 7, 2014 — Women face greater limits on their lifestyle and have more severe symptoms as a result of peripheral artery disease (PAD), but minimally invasive procedures used to unclog arteries...

Interim results from The Chocolate Bar Registry conducted in the United States demonstrate that use of the Chocolate PTA balloon achieved high rates of treatment success and limb preservation in...

GE Healthcare showcased a new suite of connected cardiovascular technologies, including several for advanced imaging and new software capabilities, at ACC 2014. New innovations included advances...

FDA Abbott Supera Self-Expanding Stent Peripheral Artery Disease

The U.S. Food and Drug Administration (FDA) approved Abbott’s Supera Peripheral Stent System to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD...

The U.S. Food and Drug Administration (FDA) cleared Cardiovascular Systems Inc.’s Diamondback 360 60 cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial...

Cordis Trieme Chocolate PTA Balloon Catheter Peripheral Artery Disease PAD

Cordis Corp. announced an agreement with TriReme Medical Inc. that grants the company exclusive distribution rights for the Chocolate PTA Balloon Catheter.